

**ATTACHMENT A**  
**Amendments to the Claims**

*This listing of claims will replace all prior versions, and listings, of claims in the application.*

1. (Original) Human anti-idiotypic antibody Fab or scFv fragment, characterized by the ability to mimic Her-2/neu tumor associated antigen.

2. (Original) The fragment of claim 1, that comprises a sequence SEQ ID No: 3 in the CDR3 region of the VH domain and a sequence SEQ ID No: 4 in the CDR3 region of the VL domain.

3. (Original) The fragment of claim 1, that comprises a sequence SEQ ID No: 5 in the CDR3 region of the VH domain and a sequence SEQ ID No: 6 in the CDR3 region of the VL domain.

4. (Currently Amended) The fragment of ~~any of claims 1 to 3~~ claim 1, which is directed against trastuzumab F(ab')<sub>2</sub>.

5. (Original) The fragment of claim 2, which comprises the aminoacid sequence SEQ ID No:1, this fragment being designated scFv 40.

6. (Original) The fragment of claim 3, which comprises the aminoacid sequence SEQ IDNo:2, this fragment being designated scFv 69.

7. (Currently Amended) A multimer of the antibody fragment defined in ~~any of claims 1 to 6~~ claim 1.

8. (Currently Amended) A pharmaceutical composition comprising an antibody fragment according to ~~any of claims 1 to 6~~ claim 1, or a multimer of the antibody fragment~~thereof according to claim 7~~, in association with a pharmaceutically acceptable carrier.

9. (Currently Amended) An ex vivo method for preparing antigen-presenting cells (APCs) useful for inducing Her-2/neu-specific protective antitumor immunity, which method comprises contacting an antigen-presenting cell with an anti-idiotypic antibody fragment according to ~~any of claims 1 to 6~~ claim 1.

10. (Original) The method of claim 9, wherein the APC is a dendritic cell.

11. (Currently Amended) An isolated APC prepared according to the method of claim 9 ~~or 10~~.

12. (Currently Amended) Use of an antibody fragment according to ~~any of claims 1 to 6~~ claim 1, or a multimer of the antibody fragment~~thereof according to claim 7~~, for the preparation of a medicament for the prevention or treatment of a tumor wherein Her-2/neu is overexpressed.

13. (Original) Use of the APC of claim 11 for the prevention or treatment of a tumor wherein Her-2/neu is overexpressed.

14. (Currently Amended) The use of claim 12 ~~or 13~~, wherein the tumor is an adenocarcinoma.

15. (Original) The use of claim 14, wherein the tumor is selected from breast cancer, ovary cancer, uterus cancer, stomach cancer and lung cancer.